IMS Continues to Outperform Market

Pharmaceutical and healthcare intelligence giant IMS Health continues its recent growth, today announcing second-quarter revenue up 11% on the year (8% at constant currencies) to $537.5m.

Operating income was up 11% (13% constant currencies) to $118.1m, and operating income growth would have been 5% (7%) with the exclusion of a merger cost of $6.0 million in Q2 2006. Diluted earning per share rose 20% to $0.36. Net income on a GAAP basis was up 17% to $73.4 million.

Chairman and CEO David R. Carlucci called the results 'solid' and said the performance was driven by strong revenue gains in the U.S., Japan and the emerging markets. He added: 'In an increasingly challenging healthcare environment, we remain focused on areas most critical to our clients, who clearly recognize the value and relevance of our capabilities and industry perspective.'

Taking the whole of the first half of 2007 together, revenues were up 12% (9% constant currencies) to $1,047.8m, and operating income was up 13% (14%) to $229.2m. Net income on a GAAP basis was $159.0 million, compared with $180.8 million in the first half of 2006.

IMS is online at www.imshealth.com.

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• IMS Health Inc
• All news